---
document_datetime: 2026-02-24 09:59:16
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/exelon-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: exelon-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.7353734
conversion_datetime: 2026-02-25 11:35:27.350951
docling_version:
  docling-serve: 1.13.1
  docling-jobkit: 1.11.0
  docling: 2.74.0
  docling-core: 2.65.2
  docling-ibm-models: 3.11.0
  docling-parse: 5.3.4
  python: cpython-313 (3.13.11)
  plaform: macOS-26.3-arm64-arm-64bit-Mach-O
---
## Exelon

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number     | Scope                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|------------------------|------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA_IN / | Q.II.f.1.a) Reduction of the shelf life of the | 23/02/2026                          |                                             | SmPC                             |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                       | finished product - Q.II.f.1.a.1 As packaged for sale - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |                                  | EMA/VR/0000328092   |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------------------------|---------------------|
| Variation type IA /                   | A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted                                                                                                                                                                                                                                                                                                                                                   | 23/01/2026 | SmPC, Annex II, Labelling and PL | EMA/VR/0000323550   |
| Variation type IB / EMA/VR/0000297093 | This was an application for a group of variations. B.III.1.b European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient - B.III.1.b.3 Updated certificate from an already approved manufacturer - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.z Other changes - Accepted B.III.1.b European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient - B.III.1.b.2 New | 09/12/2025 |                                  |                     |

<div style=\"page-break-after: always\"></div>

| intermediate/or excipient from a new or an already approved manufacturer - Accepted B.III.1.b European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient - B.III.1.b.2 New certificate for a starting material/reagent/ intermediate/or excipient from a new or an already approved manufacturer - Accepted B.III.1.b European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient - B.III.1.b.4 Deletion of certificates (in case multiple certificates exist per material) - Accepted B.III.1.b European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient - B.III.1.b.4 Deletion of certificates (in case multiple certificates exist per material) - Accepted B.III.1.b European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient - B.III.1.b.4 Deletion of certificates (in case multiple certificates exist per material) - Accepted B.III.1.b European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient - B.III.1.b.4 Deletion of certificates (in case multiple   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                  | certificates exist per material) - Accepted B.III.1.b European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient - B.III.1.b.4 Deletion of certificates (in case multiple certificates exist per material) - Accepted                                                                                                         |            |    |                   |
|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----|-------------------|
| Variation type IA /              | This was an application for a group of variations. B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.a Tightening of specification limits - Accepted B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.a Tightening of specification limits - Accepted                                                   | 11/08/2025 |    | EMA/VR/0000291442 |
| Article 61(3) / EMA/N/0000263584 | - Notification acc. Article 61(3) - Accepted Update of the product information to align the ADRs listed in sections '4. Possible side effects' of the package leaflet with section 4.8 of the SmPC and to introduce an updated image for Exelon transdermal patch (EU/1/98/066/019-050) under 'Where to apply your Exelon transdermal patch' in section '3. How to use Exelon' of the package leaflet. | 11/04/2025 | PL |                   |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000245362   | This was an application for a group of variations. B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.c Addition of a new specification parameter to the specification with its corresponding test method - Accepted B.I.a.3 Change in batch size (including batch size ranges) of active substance or intermediate used in the manufacturing process of the active substance - B.I.a.3.a Up to 10-fold increase compared to the originally approved batch size - Accepted   | 06/03/2025   |
|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|